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ABSTRACT
 
Objectives: The aim of this study is to show that if 
subcutaneous glucose 10% 0.5 ml injection around 
inflamed nerves can relieve diabetic neuropathic pain 
in comparison to control. Design: Observational cohort 
prospective study 2 months trial. Materials and 
Methods: Observational cohort prospective study with 
the following of 100 patients of type 1 and type 2 
diabetes mellitus in 2 groups each group 50 patients, 
each group 30 males, and 20 females,35 patients with 
type 2 diabetes and 15 patients type 1 diabetes all have 
diabetic peripheral neuropathy, the second group is 
considered as control. Conclusion: Diabetic 
neuropathy is considered as a great problem affecting 
most of the diabetic patients with moderate to severe 
pain. Subcutaneous glucose injection around inflamed 
nerves is considered as a new option for the treatment 
of neuropathic pain and muscle pain.  
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INTRODUCTION 
Diabetes mellitus is considered as the 
biggest global burden in the last years. 
With increasing prevalence due to modern 
lifestyles with no exercise, reaching more 
than 400 million cases all over the world, 
which put a great impact on productivity? 
The increase in diabetes occurrence is 
related to increased age, in which more 
than 20% of peoples over 60 years have 
diabetes [1]. 
 
 Diabetes mellitus is one of the most 
important causes of peripheral neuropathy 
at this time, which is mostly in the form of 
distal symmetrical polyneuropathy in more 
than 90% of patients which may be 
presented as small fiber damage with a 
burning sensation or with large fiber 
damage with numbness [2]. 
  
Distal symmetrical polyneuropathy begins 
distally from the toes and progress 
proximally in a slow fashion to include the 
feet then the legs. The most frequent 
complication is the foot infections, foot 
ulcers and there is a risk of leg amputation 
in diabetic patients with diabetic 
neuropathy [3]. Diabetic neuropathy pain 
is burning and may lead to an electric 
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shock sensation [4]. The pain is moderate 
to severe increasing at night in which may 
cause insomnia and may lead to low mood 
and anxiety [5].  
 
It is considered as a great problem as 
About 30% of diabetic patients suffered 
pain from peripheral neuropathy which is 
more common in type 2 diabetes than type 
1 [6]. 
 
Diabetic neuropathy is considered as a 
serious problem as it is present in most 
diabetic patients, and also is present in the 
prediabetes stage before the occurrence of 
hyperglycemia [7]. 
 
When diabetes mellitus is diagnosed about 
7-8% of patients have neuropathy, after 20 
years of diabetes, more than 50% of 
patients have neuropathy. [8]. 
 
Diabetic neuropathy is a consequence of 
the inability to repair nerve damage which 
leads to sensory loss. Inflammation, 
ischemia and metabolic factors are 
responsible for the pathogenesis of 
diabetic neuropathy [9]. 
 
A strong relationship is present between 
the period of diabetes and diabetic 
neuropathy [10]. Good glucose control by 
intensive insulin therapy could prevent 
diabetic neuropathy in type 1 diabetes 
[11]. But in type 2 diabetes, it is not 
evident if strict glucose control could 
prevent diabetic neuropathy [12]. 
 
Diabetic neuropathy takes place due to 
prolonged hyperglycemia which results in 
increased glycolysis rate which leads to an 
increased level of reactive insulin species 
resulting in damage of cells and impairing 
mitochondrial function. Also, prolonged 
hyperglycemia shifting glucose 
metabolism to the polyol pathway which 
leads to oxidative stress which increases 
cytokine levels and decreasing nitric oxide 
level impacting the endothelial function 
resulting in hypoxia of nerves [13]. 
Hyperglycemia cause formation of 
advanced glycation end products which 
leads to nerve damage and vascular injury 
[14]. 
 
Treating symptoms of neuropathy is the 
target of many clinicians and is guided by 
choosing a safe and effective drug [15]. 
 
The pain of diabetic neuropathy can be 
controlled by systemic FDA approved 
drugs like pregabalin, Duloxetine, and 
gabapentin or by topical drugs like 
capsaicin and lidocaine. Also, some 
dietary supplement may be used for 
treating diabetic neuropathy like alpha-
lipoic acid and acetyl-L-carnitine [16]. 
 
Prolotherapy is considered as a new option 
for the treatment of neuropathic pain and 
muscle pain. Glucose as an irritant 
material may be injected in the site of pain 
and in the tendons [17]. How glucose 
control neuropathic pain is a marvelous 
thing in which glucose hyperpolarize 
nerves by acting on potassium channels, 
and so diminishing nociceptive pain fibers 
transport [18]. Glucose solution is thought 
to give rise to inflammatory action giving 
rise to chemical inflammatory mediators 
including ILGF, EGF, PDGF, TGF-beta 
and CTGF resulting in stimulation of the 
healing process [19]. 
 
One of the mechanisms proposed to 
explain the pain-relieving effect of 
hyperosmolar glucose is blocking vanilloid 
type 1 receptor permitting the entrance of 
Ca2+ and Na+. Entrance of sodium result 
in action potential and nociception calcium 
entrance leads to the liberation of 
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substance P and calcitonin gene-related 
peptide [20], and so preventing entrance of 
sodium and potassium could decrease 
neuropathic pain [22]. 
 
MATERIALS AND METHODS 
Observational cohort prospective study 
with the following of 100 patients of type 
1 and type 2 diabetes mellitus in 2 groups 
each group 50 patients, each group 30 
males, and 20 females,35 patients with 
type 2 diabetes and 15 patients type 1 
diabetes all have diabetic peripheral 
neuropathy, the second group is 
considered as control. The ages of all 
patients are between 20 and 50 years. 
 
The first group was on subcutaneous 
glucose 0.5 ml per site around 
subcutaneous nerves in the foot region 
both on palm and sole, which is repeated 
every 2 weeks for 2 months. 
 
The aim of the study is to show if 
subcutaneous glucose 10% has a pain-
relieving effect on peripheral diabetic 
neuropathy pain. 
 
Pain severity was evaluated by using the 
Visual Analogue Scale (VAS) which is a 
numerical rating scales, with a straight 
horizontal line of 100 mm. which is 
directed from the left with severe pain to 
the right with no pain. 1-3 = mild pain, 4-6 
= moderate pain, 7-10 = severe pain. 
 
The evaluation of neuropathy was done by 
using the Michigan Neuropathy Screening 
Instrument (MNSI) after translation to the 
Arabic language, which consists a 15 self-
administered questionnaires and 
examination lower extremities which 
comprise inspection and examination of 
vibratory senses and ankle reflexes. A 
score which is more than 7 was suggested 
to be abnormal. 
 
Inclusion Criteria 
1. Patients 20 years to 50 years with type 
1 or type 2 diabetes who have 
symptoms of symmetrical peripheral 
neuropathic pain. 
2. Female patients are not pregnant. 
3. Patient has a pain score of at least 5 on 
the Visual Analogue Scale (VAS). 
4. Patients are on their antidiabetes 
medication. 
5. Patents are not on any medication for 
peripheral neuropathy. 
6. Patient must be able to complete 
questions on the Michigan Neuropathy 
Screening Instrument (MNSI).  
 
Exclusion Criteria 
1. Patient has conditions that could affect 
the evaluation of painful DPN, or non-
diabetic neurologic disorders. 
2. Patient has skin conditions in the area 
affected by the neuropathy that could 
alter sensation. 
3. Patient with history of drug abuse. 
4. Patients on any drug for diabetic 
neuropathy like pregabalin or 
gabapentin. 
5. No side effects were monitored during 
the period of treatment. 
 
RESULTS 
Patients group was compared to the 
control group before and 2 months after 
treatment of subcutaneous 10% glucose. 
Analysis of that was done using GraphPad. 
Paired ‘t’ test was done to analyze pre-post 
changes within the group and between the 
2 groups 
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Table 1: Patients received sc glucose v/s control on vas scale. 
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Table 2: Patients on sc glucose v/s c on MNSI questionnaire. 
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Table3: t test patients on sc glucose v/s control on vas score with p value less than 0.0001. 
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Table4: pts on sc glucose v/s control on MNSI questionnaire with p value less than 0.0001. 
 
 
Table 5: One sample t test for patients before and after sc glucose on vas scale with p value 
less than 0.0001. 
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Table 6: One sample t test for patients on sc glucose v/s control on MNSI questionnaire with 
p value less than 0.0001. 
 
 
 
Figure 1: Patients on sc glucose v/s control on vas score show significant decrease in pain 
scores in patients receiving glucose. 
 
 
Figure 2: Patients on sc glucose v/s control on MNSI showing significant improvement in 
neurological scores. 
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Table 7: Patients on sc glucose before and after treatment. 
 
 
 
Figure 3: Patients on sc glucose before and after treatment on vas score showing significant 
decrease of pain scores. 
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Table 8: Patients on sc glucose before and after treatment on MNSI questionnaire. 
 
 
 
Figure 4: Patients on sc glucose before and after treatment on MNSI scores showing 
significant improvement on MNSI scores. 
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The results show that subcutaneous 10% 
glucose shots showed significant reduction 
in Pain using VAS scale with mean of 
7.520 to mean of 0.5000 with p-value less 
than 0.0001 in the group who were on sc 
glucose as seen in Table 5 and Fig. 3, and 
in comparison to the control group as in 
Table 1, 3 and Fig. 1. 
 
In MNSI score with a mean of 7.020 to 
mean of 2.540 significant p-value less than 
0.0001 as seen in Table 4 and Fig. 4 in 
patients who were on sc glucose, and in 
comparison to the control group as seen in 
Table 2 and 4 and Fig. 2. 
 
DISCUSSION 
Diabetic neuropathy is prevalent in most 
type 1 and type 2 patients, in which 
presented mainly by pain, which is caused 
mainly by chronic hyperglycemia. 
Treatment is by controlling hyperglycemia 
and drugs decreasing pain [22]. 
 
Diabetic neuropathy results due to nerve 
injury and tissue damage. Pain and 
temperature nerve fibers are the most 
affected [23].  
 
Also, microcirculation is affected leading 
to muscle atrophy, foot infection, and foot 
ulcers [24]. Diabetic neuropathic pain is 
mainly localized to the foot [25].  
 
Available treatment for diabetic 
neuropathy is only for relieve of symptoms 
and don't have any effect on the progress 
of the disease. These drugs may lead to 
many side effects which cannot be 
afforded by a large number of patients 
[26].  
 
There are also trials for using other 
managements for diabetic neuropathy like 
a cold laser, acupuncture [27], 
transcutaneous electrical nerve stimulation 
(TENS). All of these procedures for pain 
relieve is still not guaranteed as effective 
[28]. 
Hypertonic glucose injection is used for 
pain relieve in various chronic 
musculoskeletal conditions. Usually, a 
small volume of hypertonic glucose 
(0.5 ml) is injected in painful sites as 
around inflamed nerves [29].  
 
In this trial glucose, 10% was injected in 
painful sites in the foot in the palm and 
sole regions. 
My finding in this study shows that 
subcutaneous glucose 10%, when injected 
by 0.5 ml in various painful sites in the 
foot, led to relieve of neuropathic pain in 
diabetic neuropathy and also led to 
improvement in nerve functions. 
 
 The restriction of my study is the few 
patients sample size. While the inclusion 
of a small number of patient’s limits and 
restricts the extrapolation of our findings 
to the general population. 
 
CONCLUSION 
As diabetic neuropathy is considered as a 
great problem affecting most of the 
diabetic patients with moderate to severe 
pain, subcutaneous glucose injection 
around inflamed nerves is considered as a 
new option for the treatment of 
neuropathic pain and muscle pain.  
The data used to support the findings of 
this study are included in the article. 
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